A Biotech 'Cure'

Drugmaker GlaxoSmithKline has had a "miserable" year, says Forbes' Robert Langreth. Sales are "stagnant"; it's facing the loss of its patent on asthma drug Advair; its diabetes treatment, Avandia, is off the market in Europe and use of the drug was restricted in the US after the company was accused of minimizing data that show it caused heart problems; and in October, it paid $750 million to settle charges that it produced tainted drugs.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

American scientists find themselves once again warning the Trump administration not to dismiss science, the New Yorker report.

A new study suggests CRISPR could be used to save coral reefs from dying off, Forbes reports.

Researchers have found that the i-motif shape of DNA previously observed in the lab also exists in human cells, and that it may serve a purpose.

In PNAS this week: a genomic, transcriptomic, and metabolomic analysis of the tea plant, Arabidopsis thaliana's adaptations to specific local environments, and more.